Acer Therapeutics Inc. (ACER) Reaches $18.28 After 4.00% Down Move; Dearborn Partners Has Cut By $985,530 Its Phillips 66 (PSX) Stake

January 14, 2018 - By Kurt Siggers

Dearborn Partners Llc decreased Phillips 66 (PSX) stake by 42.71% reported in 2017Q3 SEC filing. Dearborn Partners Llc sold 10,830 shares as Phillips 66 (PSX)’s stock declined 0.52%. The Dearborn Partners Llc holds 14,530 shares with $1.33M value, down from 25,360 last quarter. Phillips 66 now has $53.69 billion valuation. The stock increased 2.54% or $2.6 during the last trading session, reaching $104.97. About 1.85 million shares traded or 6.66% up from the average. Phillips 66 (NYSE:PSX) has risen 0.77% since January 14, 2017 and is uptrending. It has underperformed by 15.93% the S&P500.

The stock of Acer Therapeutics Inc. (NASDAQ:ACER) is a huge mover today! The stock decreased 6.26% or $1.22 during the last trading session, reaching $18.28. About 72,815 shares traded or 177.55% up from the average. Acer Therapeutics Inc. (NASDAQ:ACER) has 0.00% since January 14, 2017 and is . It has underperformed by 16.70% the S&P500.The move comes after 6 months negative chart setup for the $137.05 million company. It was reported on Jan, 14 by We have $17.55 PT which if reached, will make NASDAQ:ACER worth $5.48M less.

Since September 19, 2017, it had 0 insider purchases, and 2 selling transactions for $373,204 activity. Oyolu Chukwuemeka A. also sold $270,675 worth of Phillips 66 (NYSE:PSX) shares.

Among 18 analysts covering Phillips 66 (NYSE:PSX), 8 have Buy rating, 2 Sell and 8 Hold. Therefore 44% are positive. Phillips 66 had 64 analyst reports since August 4, 2015 according to SRatingsIntel. The stock has “Equal-Weight” rating by Barclays Capital on Wednesday, July 13. Goldman Sachs upgraded the stock to “Buy” rating in Monday, December 18 report. Jefferies maintained Phillips 66 (NYSE:PSX) rating on Wednesday, December 20. Jefferies has “Sell” rating and $79.0 target. Citigroup downgraded the stock to “Hold” rating in Wednesday, April 20 report. Mizuho maintained Phillips 66 (NYSE:PSX) rating on Monday, February 6. Mizuho has “Buy” rating and $63 target. Barclays Capital maintained Phillips 66 (NYSE:PSX) rating on Wednesday, August 2. Barclays Capital has “Equal-Weight” rating and $89 target. Goldman Sachs upgraded Phillips 66 (NYSE:PSX) on Friday, September 30 to “Neutral” rating. On Wednesday, November 15 the stock rating was maintained by UBS with “Neutral”. The company was maintained on Thursday, December 21 by Scotia Capital. The firm has “Hold” rating given on Thursday, July 6 by RBC Capital Markets.

Investors sentiment increased to 0.92 in 2017 Q3. Its up 0.07, from 0.85 in 2017Q2. It improved, as 40 investors sold PSX shares while 369 reduced holdings. 94 funds opened positions while 282 raised stakes. 353.24 million shares or 0.95% more from 349.91 million shares in 2017Q2 were reported. Mitsubishi Ufj Trust & Bk accumulated 0.16% or 949,053 shares. Rbf Limited Liability Com owns 50,000 shares or 0.58% of their US portfolio. Salem Invest Counselors has 0.17% invested in Phillips 66 (NYSE:PSX). Manchester Mngmt Ltd Llc holds 0.17% or 11,766 shares in its portfolio. Adirondack Trust holds 5,480 shares. Amica Mutual holds 36,034 shares or 0.29% of its portfolio. Becker Capital Management holds 0.83% or 263,045 shares. Marietta Invest Prns Ltd Liability Corporation, a Wisconsin-based fund reported 2,457 shares. State Of Wisconsin Board stated it has 581,845 shares. Clearbridge Ltd invested 0.15% of its portfolio in Phillips 66 (NYSE:PSX). Caprock holds 5,921 shares or 0.11% of its portfolio. Moreover, Main Street Research Ltd has 1.74% invested in Phillips 66 (NYSE:PSX). 3,416 are held by Ray Gerald L And Associate. Bailard Incorporated holds 2,322 shares. Ledyard Retail Bank has 0.05% invested in Phillips 66 (NYSE:PSX) for 4,501 shares.

Analysts await Phillips 66 (NYSE:PSX) to report earnings on February, 2. They expect $1.27 EPS, up 693.75% or $1.11 from last year’s $0.16 per share. PSX’s profit will be $649.62 million for 20.66 P/E if the $1.27 EPS becomes a reality. After $1.66 actual EPS reported by Phillips 66 for the previous quarter, Wall Street now forecasts -23.49% negative EPS growth.

Acer Therapeutics Inc. develops therapies for the treatment of serious ultra-rare diseases with critical unmet medical needs. The company has market cap of $137.05 million. The firm offers Celiprolol for vascular ehlers-danlos syndrome and ACER-001 for maple syrup urine disease . It currently has negative earnings. It also offers advancing ACER-001 for the treatment of urea cycle disorders (UCD).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:

Recent Posts

Twitter Auto Publish Powered By :